Effects of calcifediol treatment on the progression of renal osteodystrophy during continuous ambulatory peritoneal dialysis

G. Buccianti, M. L. Bianchi, G. Valenti, M. Lorenz, D. Cresseri

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Mineral metabolism was studied in 31 patients with chronic renal failure on continuous ambulatory peritoneal dialysis (CAPD) for a year. After baseline observations, 1-year calcifediol treatment was started in all the patients (100 μg/day). After therapy, progressive normalization of calcium levels was found in all patients, while plasma phosphate did not change. After therapy, plasma alkaline phosphatase and parathyroid hormone decreased significantly. 1,25-Dihydroxyvitamin D showed a slight increase, and 25-hydroxyvitamin D (extremely low at the start of the study) rose, reaching normal levels, after 1 year of treatment. Bone mineral density and bone biopsy indexes showed general improvement after calcifediol. In conclusion, calcifediol seems to act positively on the disorders of mineral metabolism in CAPD.

Original languageEnglish
Pages (from-to)353-356
Number of pages4
JournalNephron
Volume56
Issue number4
Publication statusPublished - 1990

Fingerprint

Chronic Kidney Disease-Mineral and Bone Disorder
Calcifediol
Continuous Ambulatory Peritoneal Dialysis
Minerals
Therapeutics
Parathyroid Hormone
Bone Density
Chronic Kidney Failure
Alkaline Phosphatase
Phosphates
Calcium
Biopsy
Bone and Bones

Keywords

  • Alkaline phosphatase
  • Bone biopsy
  • Bone mineral density
  • Calcifediol
  • CAPD
  • Dialysis
  • Mineral metabolism
  • PTH
  • Renal osteodystrophy
  • Vitamin D metabolites

ASJC Scopus subject areas

  • Nephrology

Cite this

Effects of calcifediol treatment on the progression of renal osteodystrophy during continuous ambulatory peritoneal dialysis. / Buccianti, G.; Bianchi, M. L.; Valenti, G.; Lorenz, M.; Cresseri, D.

In: Nephron, Vol. 56, No. 4, 1990, p. 353-356.

Research output: Contribution to journalArticle

Buccianti, G. ; Bianchi, M. L. ; Valenti, G. ; Lorenz, M. ; Cresseri, D. / Effects of calcifediol treatment on the progression of renal osteodystrophy during continuous ambulatory peritoneal dialysis. In: Nephron. 1990 ; Vol. 56, No. 4. pp. 353-356.
@article{93f35714bd62463bb984f7f9d53ab96c,
title = "Effects of calcifediol treatment on the progression of renal osteodystrophy during continuous ambulatory peritoneal dialysis",
abstract = "Mineral metabolism was studied in 31 patients with chronic renal failure on continuous ambulatory peritoneal dialysis (CAPD) for a year. After baseline observations, 1-year calcifediol treatment was started in all the patients (100 μg/day). After therapy, progressive normalization of calcium levels was found in all patients, while plasma phosphate did not change. After therapy, plasma alkaline phosphatase and parathyroid hormone decreased significantly. 1,25-Dihydroxyvitamin D showed a slight increase, and 25-hydroxyvitamin D (extremely low at the start of the study) rose, reaching normal levels, after 1 year of treatment. Bone mineral density and bone biopsy indexes showed general improvement after calcifediol. In conclusion, calcifediol seems to act positively on the disorders of mineral metabolism in CAPD.",
keywords = "Alkaline phosphatase, Bone biopsy, Bone mineral density, Calcifediol, CAPD, Dialysis, Mineral metabolism, PTH, Renal osteodystrophy, Vitamin D metabolites",
author = "G. Buccianti and Bianchi, {M. L.} and G. Valenti and M. Lorenz and D. Cresseri",
year = "1990",
language = "English",
volume = "56",
pages = "353--356",
journal = "Experimental Nephrology",
issn = "0028-2766",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Effects of calcifediol treatment on the progression of renal osteodystrophy during continuous ambulatory peritoneal dialysis

AU - Buccianti, G.

AU - Bianchi, M. L.

AU - Valenti, G.

AU - Lorenz, M.

AU - Cresseri, D.

PY - 1990

Y1 - 1990

N2 - Mineral metabolism was studied in 31 patients with chronic renal failure on continuous ambulatory peritoneal dialysis (CAPD) for a year. After baseline observations, 1-year calcifediol treatment was started in all the patients (100 μg/day). After therapy, progressive normalization of calcium levels was found in all patients, while plasma phosphate did not change. After therapy, plasma alkaline phosphatase and parathyroid hormone decreased significantly. 1,25-Dihydroxyvitamin D showed a slight increase, and 25-hydroxyvitamin D (extremely low at the start of the study) rose, reaching normal levels, after 1 year of treatment. Bone mineral density and bone biopsy indexes showed general improvement after calcifediol. In conclusion, calcifediol seems to act positively on the disorders of mineral metabolism in CAPD.

AB - Mineral metabolism was studied in 31 patients with chronic renal failure on continuous ambulatory peritoneal dialysis (CAPD) for a year. After baseline observations, 1-year calcifediol treatment was started in all the patients (100 μg/day). After therapy, progressive normalization of calcium levels was found in all patients, while plasma phosphate did not change. After therapy, plasma alkaline phosphatase and parathyroid hormone decreased significantly. 1,25-Dihydroxyvitamin D showed a slight increase, and 25-hydroxyvitamin D (extremely low at the start of the study) rose, reaching normal levels, after 1 year of treatment. Bone mineral density and bone biopsy indexes showed general improvement after calcifediol. In conclusion, calcifediol seems to act positively on the disorders of mineral metabolism in CAPD.

KW - Alkaline phosphatase

KW - Bone biopsy

KW - Bone mineral density

KW - Calcifediol

KW - CAPD

KW - Dialysis

KW - Mineral metabolism

KW - PTH

KW - Renal osteodystrophy

KW - Vitamin D metabolites

UR - http://www.scopus.com/inward/record.url?scp=0025001274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025001274&partnerID=8YFLogxK

M3 - Article

C2 - 2079992

AN - SCOPUS:0025001274

VL - 56

SP - 353

EP - 356

JO - Experimental Nephrology

JF - Experimental Nephrology

SN - 0028-2766

IS - 4

ER -